CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 625 enrolled
Drug / intervention
DAR-901 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02712424
NCT02712424Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study of the Prevention of Infection With Mycobacterium Tuberculosis Among Adolescents Who Have Previously Received BCG

Dartmouth-Hitchcock Medical Center·interventional·Posted Mar 18, 2016·Updated May 11, 2021

In Brief

A Phase 2 clinical trial evaluating DAR-901 and Sterile saline placebo for Tuberculosis. Completed, enrolled 625 participants across 1 site.

Detailed Summary

DAR-901 booster vaccine or placebo will be administered to adolescents in Tanzania primed with BCG to determine if immunization reduces the risk of TB infection

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTuberculosis
CountriesTanzania
CollaboratorsMuhimbili University of Health and Allied Sciences

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 18, 2016
Enrollment StartMar 1, 2016
Primary CompletionFeb 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 10.3 years ago

Interventions

DAR-901biological

Sterile saline placebobiological